Karine Tawagi, assistant Professor of Clinical Medicine and Hematology/Oncology Fellowship Program Director at the University of Illinois Chicago, shared on X:
“Phase II proposal for PTEN-deficient mAMPS.
Patients with greater than 90% PTEN loss randomized to capivasertib, abiraterone and androgen deprivation therapy (ADT) or an upfront chemotherapy triplet with docetaxel, abiraterone and ADT, followed by capivasertib maintenance.
A question under consideration in the study design is whether to administer maintenance capivasertib or introduce it at progression, while evaluating second radiographic progression-free survival (rPFS2).”
About Capivasertib Strategies in PTEN-Deficient Prostate Cancer
PTEN deficiency is associated with activation of the PI3K/AKT signaling pathway and poorer outcomes in metastatic prostate cancer. Targeting this pathway with capivasertib, an AKT inhibitor, represents an important development in biomarker-directed treatment.
The Phase III CAPItello-281 trial evaluated capivasertib plus abiraterone and ADT in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer. The study enrolled 1,012 patients and demonstrated improved radiographic progression-free survival (rPFS) compared with abiraterone-based treatment without capivasertib.
An updated analysis published in October 2026 reported median rPFS of 35.5 versus 26.0 months, while median overall survival was 57.4 versus 46.5 months. The updated overall survival analysis was descriptive and did not meet the prespecified statistical significance threshold.
Read more articles about Prostate Cancer on OncoDaily.
